Entera Bio: A Game Changer in Osteoporosis in the offing!
Entera Bio Ltd. (NASDAQ: ENTX), a clinical-stage biotechnology company, developing leading-edge orally delivered large molecule therapeutics, announced pivotal 6-month bone mineral density (BMD) results from the Phase 2 clinical trial of EB613, intended for the treatment of osteoporosis. EB613, the Company’s lead candidate for the...
